Introduction

Biopharmaceutical Science involves study of the discovery, development and processing of modern, medical drugs by artificially growing some or all of the components utilising cell culture technologies. The processes involved are more biological-based as compared to the more chemical-based processes associated with small-molecule pharmaceutical products. The Medical Biotechnology and Biopharmaceutical sectors are among the fastest growing in the Life Sciences area both nationally and internationally.

They are proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) used for therapeutic or in vivo diagnostic purposes, and are produced by means other than direct extraction from a native (non-engineered) biological source. Biopharmaceuticals are medical drugs produced using biotechnology. They are proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) used for therapeutic or in vivo diagnostic purposes, and are produced by means other than direct extraction from a native (non-engineered) biological source. The first such substance approved for therapeutic use was recombinant human insulin (rHI, trade name Humulin), which was developed by Genentech and marketed by Eli Lily in 1982. The large majority of biopharmaceutical products are pharmaceuticals that are derived from life forms. Small molecule drugs are not typically regarded as biopharmaceutical in nature by the industry.